An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists.
Rheumatoid arthritis (RA) is a chronic, progressive, inflammatory disease that affects approximately 0.5-1% of the adult population. The introduction of new disease-modifying antirheumatic drugs (DMARDs) such as leflunomide, anakinra and the tumour necrosis factor (TNF)-alpha antagonists (infliximab, etanercept and adalimumab) have transformed the management of RA. In particular, the last class of agents has generated substantial controversy. Costing between 16,000 US dollars and 20,000 US dollars per patient-year (2001 values), the potential greater efficacy of treatment with TNFalpha antagonists comes at much higher drug costs, making these agents natural candidates for cost-effectiveness analyses (CEAs).A MEDLINE search (until 31 January 2004) identified six original CEAs evaluating TNFalpha antagonists in RA. The aim of a CEA is to facilitate the allocation of scarce health resources and to inform policy decisions. However, to enhance the reliability and relevance of these analyses to policy makers, there must be similarity between the methodologies used. Recently, the OMERACT (Outcome Measures in Rheumatoid Arthritis Clinical Trials) group produced a document to define such a reference case; the OMERACT document was used as a foundation to structure comparisons and highlight discrepancies. The methodologies employed in each analysis differed; in particular, disparate time horizons, comparators, quantities of drug and treatment sequences prohibit the comparison of cost effectiveness between studies. Outcomes also differed between the analyses. Most reported health-related quality of life (HR-QOL) in quality-adjusted life-years (QALYs). The QALYs metric was based on preference scores that were typically derived from linear regressions using the Health Assessment Questionnaire (HAQ). However, models also used American College of Rheumatology (ACR) criteria, as well as the disease activity score (DAS). Common to all studies was the lack of data from long-term randomised studies where efficacy and resource consumption in comparison with standard care has been investigated. As such, investigators combined short-term randomised control trial data with that of a long-term observational cohort, and modelled cost effectiveness over an appropriate time horizon. In addition, most analyses lacked rigorous sensitivity analysis to examine the impact of uncertainty in the parameters. Those analyses that examined time horizons of 6 months and 1 year published incremental cost-effectiveness ratios (ICERs) of 34,800 US dollars per ACR 70% response criteria (ACR70) weighted response (duration 6 months, 1999 values) and 96,166 US dollars (duration 1 year, 2002 values). Analyses that modelled costs and health outcomes beyond the first year reported ICER estimates ranging between 26,800 US dollars (patients' lifetime, 1998 values) and 40,308 US dollars (10 years, 2002 values). In terms of HR-QOL, the analyses reported incremental QALYs that ranged from 0.116 (over 19 years) to 1.6 (over 10 years). Discounted costs of therapy ranged from 30,362 US dollars (10 years, 2002 values) to 93,000 US dollars (22 years, 1998 values), and comparator costs ranged from 22,593 US dollars (10 years, 2002 values) to 84,000 US dollars (22 years, 1998 values).
Bansback
Nick J
NJ
Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK.
Regier
Dean A
DA
Ara
Roberta
R
Brennan
Alan
A
Shojania
Kamran
K
Esdaile
John M
JM
Anis
Aslam H
AH
Marra
Carlo A
CA
D018501:Antirheumatic Agents / Q000191:economics* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006801:Humans; D011788:Quality of Life
D018501:Antirheumatic Agents
J Rheumatol. 1999 Nov;26(11):2337-43
10555887
Lancet. 1999 Dec 4;354(9194):1932-9
10622295
Ann Rheum Dis. 2002 Sep;61(9):793-8
12176803
J Rheumatol. 2002 Sep;29(9):1851-7
12233878
Arthritis Rheum. 1992 Oct;35(10):1117-25
1358078
Ann Rheum Dis. 2001 Nov;60 Suppl 3:iii2-5
11890647
Arthritis Rheum. 2003 Sep;48(9):2425-33
13130461
J Rheumatol. 1995 Jun;22(6):1037-42
7674227
Health Qual Life Outcomes. 2004 Jan 13;2:5
14720300
Semin Arthritis Rheum. 2000 Apr;29(5):305-20
10805355
Rheumatology (Oxford). 2004 Feb;43(2):206-10
12923291
J Rheumatol. 2003 May;30(5):941-7
12734886
J Rheumatol. 2003 Apr;30(4):891-6
12672224
Arthritis Rheum. 2002 Feb;46(2):328-46
11840435
Arthritis Rheum. 2002 Dec 15;47(6):655-61
12522841
J Rheumatol. 1992 Dec;19(12):1885-94
1294735
J Health Econ. 1995 Jun;14(2):171-89
10154656
Arthritis Rheum. 1978 Sep-Oct;21(7):827-33
100122
Arthritis Rheum. 2003 Nov;48(11):3046-54
14613265
Ann Rheum Dis. 2002 Dec;61(12):1055-9
12429534
J Clin Epidemiol. 2003 Apr;56(4):317-25
12767408
N Engl J Med. 1997 Jul 17;337(3):141-7
9219699
Arthritis Rheum. 2003 Jan;48(1):35-45
12528101
J Rheumatol. 2001 Mar;28(3):648-56
11296976
Health Econ. 1997 May-Jun;6(3):253-9
9226143
Health Econ. 1997 Sep-Oct;6(5):505-10
9353651
N Engl J Med. 1995 Jul 20;333(3):137-41
7791814
J Rheumatol. 1984 Dec;11(6):819-27
6520836
Med Care. 2003 Jul;41(7):791-801
12835603
Ann Rheum Dis. 2004 Jan;63(1):4-10
14672883
Arthritis Rheum. 2003 Oct;48(10):2750-62
14558079
Ann Intern Med. 2001 Apr 17;134(8):695-706
11304108
Rheumatology (Oxford). 2004 Jan;43(1):4-6
14523227
J Rheumatol. 2001 Jul;28(7):1505-10
11469454
Clin Ther. 2003 Sep;25(9):2431-47
14604742
J Rheumatol. 1988 Oct;15(10):1480-8
3204597
J Rheumatol. 2003 Oct;30(10):2268-74
14528528
Arthritis Rheum. 1999 Jun;42(6):1209-18
10366114
Rheumatology (Oxford). 2000 Jan;39(1):28-33
10662870
Br J Rheumatol. 1993 Mar;32 Suppl 1:28-37
8448634
Annu Rev Public Health. 2000;21:587-611
10884966
Clin Rheumatol. 1987 Sep;6 Suppl 2:93-102
3480088
Ann Med. 2001 Jul;33(5):358-70
11491195
Arthritis Rheum. 2001 Dec;44(12):2746-9
11762934
Soc Sci Med. 2005 Apr;60(7):1571-82
15652688
Arthritis Rheum. 1984 May;27(5):522-9
6721884
J Rheumatol. 2003 Jan;30(1):167-78
12508408
Arthritis Rheum. 1998 Dec;41(12 ):2196-204
9870876
Arthritis Rheum. 2003 Jun;48(6):1530-42
12794820
Pharmacoeconomics. 1999 Nov;16(5 Pt 1):433-48
10662391
J Rheumatol. 2001 May;28(5):1163-9
11361207
Br J Rheumatol. 1997 May;36(5):551-9
9189057
Cardiology. 1989;76(1):71-7
2706647
Lancet. 2002 Apr 6;359(9313):1173-7
11955534
Rheumatology (Oxford). 2000 Sep;39(9):975-81
10986302
Pharmacoeconomics. 2001;19(8):811-8
11596833
Pharmacoeconomics. 1994 Apr;5(4):286-98
10147238
Med Decis Making. 1998 Jul-Sep;18(3):337-46
9679999
Clin Rheumatol. 2002 Nov;21(6):478-87
12447631
Rheumatology (Oxford). 2000 Jun;39(6):603-11
10888704
Ann Pharmacother. 2003 Sep;37(9):1256-65
12921510
Arthritis Rheum. 2003 Feb;48(2):313-8
12571838
Arthritis Rheum. 1995 Oct;38(10):1351-62
7575685
Arthritis Rheum. 1995 Jun;38(6):727-35
7779114
Br J Rheumatol. 1998 Dec;37(12):1324-9
9973158
Value Health. 2003 Sep-Oct;6(5):505-21
14627057
Arthritis Rheum. 1997 Sep;40(9):1580-6
9324011
Rheumatology (Oxford). 2004 May;43(5):677-8
15103038
Arthritis Rheum. 2003 Jan;48(1):54-8
12528103
Am J Med. 2002 Oct 1;113(5):400-8
12401535
Arthritis Rheum. 2000 Oct;43(10):2316-27
11037892
Health Econ. 2002 Jul;11(5):415-30
12112491
Br J Rheumatol. 1997 Aug;36(8):878-83
9291857
Public Health Rep. 1978 Sep-Oct;93(5):493-588
100825
Curr Opin Rheumatol. 1998 Mar;10(2):136-40
9567209
Arthritis Rheum. 1999 Feb;42(2):347-56
10025930
J Rheumatol Suppl. 1998 Jul;53:8-12
9666412
Med Care. 2000 Jun;38(6):583-637
10843310
Arthritis Rheum. 2003 Feb 15;49(1):64-70
12579595
Drug Intell Clin Pharm. 1985 Dec;19(12):916-9
4085350
Arthritis Rheum. 2002 Mar;46(3):625-31
11920397
Ann Rheum Dis. 2000 Dec;59(12):966-74
11087700
Arthritis Rheum. 2002 Sep;46(9):2287-93
12355475
Health Econ. 2003 May;12(5):421-7
12720259
Rheumatology (Oxford). 2003 Feb;42(2):326-35
12595631
Health Technol Assess. 2002;6(21):1-110
12387732
JAMA. 2003 Jun 25;289(24):3229-30
12824197
Acta Orthop Scand. 1992 Apr;63(2):207-12
1590060
J Rheumatol. 1991 Jul;18(7):1008-14
1920305
J Rheumatol Suppl. 1996 Mar;44:72-4
8833058
Arthritis Rheum. 2000 Jan;43(1):22-9
10643696
Ann Rheum Dis. 2000 Nov;59(11):892-7
11053068
J Rheumatol. 1993 Mar;20(3):579-81
8478878
Rheumatology (Oxford). 2004 Jan;43(1):62-72
12890861